Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial"

被引：1

作者：

Sullivan, Ivana ^{[1
]}

Planchard, David ^{[1
]}

机构：

[1] Gustave Roussy, Dept Med Oncol, 114 Rue Edouard Vaillant, F-94800 Villejuif, France

来源：

JOURNAL OF THORACIC DISEASE | 2016年 / 8卷 / 10期

关键词：

ADULT PATIENTS PTS; ALK-INHIBITOR; CONFER RESISTANCE; SINGLE-ARM; OPEN-LABEL; CRIZOTINIB; NSCLC; CERITINIB; CHEMOTHERAPY; MUTATIONS;

D O I：

10.21037/jtd.2016.10.57

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：E1287 / E1292

页数：6

共 50 条

[31] Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
Park, Heae Surng
Lee, June Koo
Kim, Dong-Wan
Kulig, Kimary
Kim, Tae Min
Lee, Se-Hoon
Jeon, Yoon-Kyung
Chung, Doo Hyun
Heo, Dae Seog
LUNG CANCER, 2012, 77 (02) : 288 - 292
[32] IMMUNOHISTOCHEMICAL SCREENING FOR ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENT IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
Lee, June Koo
Park, Heae Surng
Kim, Dong-Wan
Kulig, Kimary
Kim, Tae Min
Lee, Se-Hoon
Jeon, Yoon-Kyung
Chung, Doo Hyun
Heo, Deo Seog
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S294 - S295
[33] EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
Kerstein, D.
Gettinger, S.
Gold, K.
Langer, C. J.
Shaw, A. T.
Bazhenova, L. A.
Salgia, R.
Dorer, D. J.
Conlan, M. G.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2015, 26
[34] Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
Chen, Joseph
O'Gorman, Melissa T.
James, Lee P.
Klamerus, Karen J.
Mugundu, Ganesh
Pithavala, Yazdi K.
CLINICAL PHARMACOKINETICS, 2021, 60 (10) : 1313 - 1324
[35] An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer
Ai, Xinghao
Shen, Shengping
Shen, Lan
Lu, Shun
BIOCHIMIE, 2015, 112 : 111 - 120
[36] Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
Joseph Chen
Melissa T. O’Gorman
Lee P. James
Karen J. Klamerus
Ganesh Mugundu
Yazdi K. Pithavala
Clinical Pharmacokinetics, 2021, 60 : 1313 - 1324
[37] Economic burden of brain metastases in patients with anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung
Lin, Huamao Mark
Pan, Lucy
Hou, Peijie
Huang, Hui
Desai, Avinash
Jahanzeb, Mohammad
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
[38] Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer
Serritella, Anthony, V
Bestvina, Christine M.
THORACIC SURGERY CLINICS, 2020, 30 (02) : 137 - 146
[39] Design of ALTA-1 L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)positive non-small cell lung cancer (NSCLC).
Tiseo, Marcello
Popat, Sanjay
Gettinger, Scott N.
Peters, Solange
Haney, Jeff
Kerstein, David
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[40] ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive, advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
Popat, S.
Tiseo, M.
Gettinger, S.
Peters, S.
Haney, J.
Kerstein, D.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →